Results 11 to 20 of about 1,194,975 (181)

Drug Development Concerning Metallo-β-Lactamases in Gram-Negative Bacteria [PDF]

open access: yesFrontiers in Microbiology, 2022
β-Lactams have been a clinical focus since their emergence and indeed act as a powerful tool to combat severe bacterial infections, but their effectiveness is threatened by drug resistance in bacteria, primarily by the production of serine- and metallo-β-
Xiuyun Li
exaly   +4 more sources

Metallo-β-Lactamases and Aptamer-Based Inhibition

open access: yesPharmaceuticals, 2011
An evolution of antibiotic-resistant bacteria has resulted in the need for new antibiotics. β-Lactam based drugs are the most predominantly prescribed antibiotics to combat bacterial infections; however, production of β-lactamases, which catalyze the ...
Sung-Kun Kim   +3 more
doaj   +2 more sources

Elucidation of critical chemical moieties of metallo-β-lactamase inhibitors and prioritisation of target metallo-β-lactamases. [PDF]

open access: yesJ Enzyme Inhib Med Chem
The urgent demand for effective countermeasures against metallo-β-lactamases (MBLs) necessitates development of novel metallo-β-lactamase inhibitors (MBLIs).
Lee JH   +7 more
europepmc   +3 more sources

A DNA aptamer reveals an allosteric site for inhibition in metallo-β-lactamases. [PDF]

open access: yesPLoS ONE, 2019
The hydrolysis of β-lactam antibiotics by β-lactamase enzymes is the most prominent antibiotic resistance mechanism for many pathogenic bacteria. Out of this broad class of enzymes, metallo-β-lactamases are of special clinical interest because of their ...
Nazmul H Khan   +6 more
doaj   +2 more sources

Dynamically chiral phosphonic acid-type metallo-β-lactamase inhibitors

open access: yesCommunications Chemistry
Abstract Antibiotic resistance is a growing global health threat that risks the lives of millions. Among the resistance mechanisms, that mediated by metallo-β-lactamases is of particular concern as these bacterial enzymes dismantle most β-lactam antibiotics, which are our widest applied and cheapest to produce antibiotic agents.
Kinga Virág Gulyás   +19 more
openaire   +6 more sources

Strategies to Name Metallo-β-Lactamases and Number Their Amino Acid Residues. [PDF]

open access: yesAntibiotics (Basel), 2023
Metallo-β-lactamases (MBLs), also known as class B β-lactamases (BBLs), are Zn(II)-containing enzymes able to inactivate a broad range of β-lactams, the most commonly used antibiotics, including life-saving carbapenems. They have been known for about six
Oelschlaeger P, Kaadan H, Dhungana R.
europepmc   +2 more sources

Discovery of potential inhibitors against New Delhi metallo-β-lactamase-1 from natural compounds: in silico-based methods

open access: yesScientific Reports, 2021
New Delhi metallo-β-lactamase variants and different types of metallo-β-lactamases have attracted enormous consideration for hydrolyzing almost all β-lactam antibiotics, which leads to multi drug resistance bacteria.
Azhar Salari-jazi   +4 more
doaj   +1 more source

Novel metallo β-lactamase mediated by aShigella flexneriplasmid [PDF]

open access: yesFEMS Microbiology Letters, 1998
Novel carbapenem-hydrolyzing beta-lactamase (newly named MET-1) encoded on a transferable plasmid pMS390 from Shigella flexneri JS19622 was purified. The molecular weight was 28,000 by SDS-PAGE and the isoelectric point was higher than 9.3. This beta-lactamase favorably hydrolyzed classical cephalosporins and oxyimino-cephalosporins rather than ...
K, O'Hara   +4 more
openaire   +2 more sources

Carbapenem-Resistant Klebsiella pneumoniae in Large Public Acute-Care Healthcare System, New York, New York, USA, 2016–2022

open access: yesEmerging Infectious Diseases, 2023
Controlling the spread of carbapenem-resistant Enterobacterales is a global priority. Using National Healthcare Safety Network data, we characterized the changing epidemiology of carbapenem-resistant Klebsiella pneumoniae (CRKP) in a large public health
Jennifer Lee   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy